|
|
|
J. JOSEPH KIM, Ph. D. HAS BEEN DESIGNATED
A YOUNG GLOBAL LEADER IN 2006 |
J. Joseph Kim joins 175 leading executives,
public figures and intellectuals under the age of 40 from 50 countries
who have been selected to collectively shape the future.
Geneva, Switzerland – January 9, 2006 – The Forum
of Young Global Leaders, an affiliate of the World Economic Forum, proudly
announces today that J. Joseph Kim, Ph.D., Co-Founder, President and Chief
Executive Officer or VGX Pharmaceuticals has been named a Young Global
Leader 2006. He is one of 41 North Americans chosen to become Young Global
Leaders in 2006 and will join a global community now including 410 leaders
from all regions and stakeholder groups.
Established in 2004 by Professor Klaus Schwab, Executive Chairman of the
World Economic Forum, the Forum of Young Global Leaders is a unique, multi-stakeholder
community of the world’s most extraordinary leaders who are 40 years
old or younger and who are ready to dedicate a part of their time and
energy to jointly work towards a better future. They engage together in
the 2020 Initiative, a comprehensive endeavour, to understand current
and future trends, risks and opportunities both at global and regional
levels, formulate a positive vision for the world in 2020 and put forward
concrete strategies to translate their vision into action.
Each year a new class of around 200 YGLs is selected for a five year membership,
ultimately forming a community of 1,111 by 2009. The 2006 class was chosen
from among 3,500 candidates by the Forum of Young Global Leaders’
Nomination Committee, featuring 28 international media leaders, including
Carl-Johan Bonnier of Bonnier AB in Sweden, Arthur Sulzberger, the publisher
of the New York Times, Tom Glocer, chief executive of Reuters and Rui
Chenggang, Director and Anchor of China Central Television in the People’s
Republic of China. The Committee is chaired by Her Majesty Queen Rania
of the Hashemite Kingdom of Jordan.
During their first meeting in Zermatt, Switzerland and throughout 2005,
Young Global Leaders formed task forces addressing priority global challenges
for 2020 in the areas of development and poverty, global governance and
security, environment, education, and health. In addition, a delegation
of Young Global Leaders visited the earthquake-affected areas of Pakistan
in December 2005 as a first effort in supporting disaster relief and long-term
reconstruction.
The Young Global Leaders will meet as a community at their Annual Summit
in Vancouver, Canada, 9-12 June 2006, when they will engage together in
the 2020 Initiative, a comprehensive endeavourer, to understand current
and future trends, risks and opportunities at both the global and regional
levels, formulate a positive vision for the world in 2020 and put forward
concrete strategies to translate their vision into action.
For more information and a detailed list of all Young Global Leaders,
please visit www.younggloballeaders.org.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
The Forum
of Young Global Leaders is an independent, Geneva, Switzerland-based
foundation whose mission is to build a unique, multi-stakeholder community
of the world’s most extraordinary leaders under the age of 40 and
give them a platform to collaborate and shape best practices for the future
of the world. Each year we identify and mobilize a new group of 200 exceptional
men and women in business, politics, academia, the media and civil society
from every region in the world. Together, they form a powerful international
force for the global common good.
About VGX Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2006 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Vice President
Tel 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
